
Opinion|Videos|April 8, 2024
Safety Profile of GVHD Treatment Options
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































